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Somatostatin activates particulate guanylate cyclase in cultured rat
mesangial cells. Although the ability of somatostatin (ST) to relax
cultured rat mesangial cells has recently been described, the intimate
cellular mechanisms responsible for this effect have not been adequately
clarified. The present experiments were designed to test the hypothesis
that cyclic GMP (cGMP) could be involved in the genesis of this
relaxation. ST increased cGMP synthesis by cultured rat mesangial cells, in
basal conditions and in the presence of isobutylmethylxanthine or zapri-
nast. This effect was dose-dependent, with a threshold value of about 1 flM
and a maximal response at ST concentrations between 0.1 and 1 jsM. This
increased cGMP synthesis was dependent on the stimulation by ST of a
particulate guanylate cyclase, as the synthesis of cGMP by a particulate
membrane fraction obtained from the cells increased in the presence of
ST. When the cGMP-specific phosphodiesterase of mesangial cells was
blocked with zaprinast, the ST-dependent relaxation, assessed both by
morphological and biochemical criteria, significantly increased with re-
spect to the experiments performed without zaprinast. These results
support a role for cGMP in the ST-dependent relaxation of cultured rat
mesangial cells. The increased cGMP synthesis appears to be the conse-
quence of the activation of some form of particulate guanylate cyclase.
Recently, we have demonstrated the ability of somatostatin
(ST) to relax cultured rat mesangial cells [1]. This relaxing effect
seems to be independent of either the secondary release by the
cells of other metabolites with vasorelaxant properties or the
cellular activation of the adenylate cyclase or soluble guanylate
cyclase systems [1]. Moreover, the proliferation of these cells also
appears to be modulated by ST, as the peptide stimulates cell
proliferation in quiescent cells whereas it inhibits it in growing
cells [2]. The mechanisms responsible for these effects are un-
known. Several intracellular second messenger systems have been
described for ST, which differ as a function of the cellular system
studied or the effect tested, but the most widely described ones are
those related to its ability to modify adenylate cyclase activity [3,
4], to modulate transmembrane calcium fluxes [5, 6] or even, as
recently published, to stimulate the activity of some specific
cellular phosphatases [7]. However, our recent work [2] supports
a role for cyclic GMP in the antiproliferative effect of ST on
cultured rat mesangial cells. In addition, atrial natriuretic peptide,
which shares with ST the relaxant and antiproliferative properties
in mesangial cells [8, 9], seems to exert its main actions in these
cells through an activation of a specific particulate guanylate
cyclase [10—12). Taking into account these facts, the present
experiments were designed to assess the role of the cyclic GMP
system as a mediator of ST actions in cultured rat mesangial cells.
Methods
Mesangial cell culture
Renal glomeruli were isolated from Wistar rats weighing 100 to
150 g by successive mechanical sieving (150 and 50 .tm) in sterile
conditions. Thereafter, glomeruli were treated with collagenase,
plated in plastic culture flasks and incubated as described. The
culture medium consisted of RPMI 1640 supplemented with 10%
FCS, L-glutamine (1 mM), penicillin (0.66 g/ml), streptomycin
sulfate (60 j.tg/ml), and buffered with Hepes, pH 7.2. The identity
of the cells was confirmed by morphological and functional
criteria [1, 2, 8].
Measurement of cGMP synthesis by cultured rat mesangial cells
The experiments were performed on primary cultures of me-
sangial cells. The cells were washed twice with 2 ml of fresh
Tris-glucose buffer (Tris 20 mivi, NaCl 130 mr.t, KCI 5 mM, sodium
acetate 10 m, glucose 5 mrvi, pH 7.45), and then preincubated for
five minutes at 37°C in the same buffer containing 2.5 mM Ca2,
with or without 0.5 mrvi isobutylmethylxanthine (IBMX) or 1 .LM
zaprinast (Z), a specific cGMP phosphodiesterase inhibitor. So-
matostatin at different concentrations or buffer (10 j.d in both
case) were added to the incubation media, and cells were incu-
bated for five minutes under these conditions. The medium was
aspirated, and 1 ml of cold ethanol was added to the flasks, which
were maintained in cold ice for 30 minutes. The cellular extracts
were centrifuged for 20 minutes at 2000 X g, and the supernatant
fraction was evaporated to dryness. The cyclic GMP concentra-
tions were determined by radioimmunoassay (Amersham Inter-
national, Buckinghamshire, UK), as previously described [13], and
corrected for protein content.
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Measurement of the particulate guanylate cyclase activity in
cultured rat mesangial cells
The activity of particulate guanylate cyclase in cultured mesang-
ial cells was measured as described [14], but following two
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different experimental designs. In the first one, membrane frac-
tions were obtained from a pooi of different culture flasks and
then distributed in aliquots which were analyzed with or without
ST. In the second one, the membrane fractions of each cultured
flask were divided in two aliquots, which were subsequently tested
both in the presence and in the absence of ST. In every case, cells
were processed as follows. After washing the culture dishes with
50 mM Tris-HCI, pH 7.6, containing 150 m sodium chloride, the
cells were scraped off the dishes and collected by centrifugation
for five minutes at 500 X g. The cell pellet was resuspended in 1
ml of 50 mM Tris-HC1, pH 7.6, containing 1 mvi EDTA, 0.2 mM
phenylmethylsulfonyl fluoride, and 0.01% bacitracin (Buffer A).
After homogenization with a Polytron, the homogenate was
centrifuged at 100,000 x g for one hour at 4°C. The supernatant
fraction was aspirated, and the pellet was resuspended in 1 ml of
Buffer A, homogenized, and centrifuged as described above. The
pellet was resuspended in 50 m Tris-HC1, pH 7.6, and assayed
for guanylate cyclase activity.
A 10 pi aliquot of the particulate fraction was added to tubes
containing 80 p.1 of a reaction mixture containing (final concen-
trations) 50 m'vi Tris-HC1, pH 7.6, 4 m magnesium chloride, 1
mM GTP, 1 mM isobutylmethylxanthine, 0.01% bacitracin, and a
GTP-regenerating system that consisted of 15 mri creatine phos-
phate and 20 j.tg of creatine pkosphokinase. After the incubation
at 37°C for 10 minutes with or without ST (1 p.M, final concen-
tration) the reaction was stopped by the addition of 900 ,ii of 50
m sodium acetate, pH 4.0 followed by heating at 90°C for three
minutes. The heated incubation mixture was centrifuged at 2000
X g for 20 minutes, and the supernatant fraction was evaporated
to dryness. The amount of cyclic GMP generated was determined
in the dry extract by radioimmunoassay. Data were corrected for
protein concentration.
Rat mesangial cell contraction and pharmacological blockade of
the cGMP-specific phosphodiesterase
These experiments were devoted to assessing the contractile
response of mesangial cells, in the presence of ST, when the
cGMP-specific phosphodiesterase was blocked with Z. Contrac-
tion was evaluated by morphological and biochemical criteria. The
changes in cell shape were monitored by taking microphotographs
at variable times, as previously described [1, 8]. Cells were
incubated for 10 minutes at room temperature with Z (1 p.M final
concentration) or with an equivalent buffer volume. Thereafter,
ST at different final concentrations (100 M to 1 p.M) or angioten-
sin II (Ang II, 10 nM) were successively added to the different
culture flasks, with a 10 minutes interval. Microphotographs were
taken just before Ang II addition and after 30 minutes of
incubation. Planar cell surface areas (PCSA) were measured
according to previous descriptions [1, 8].
Phosphorylation of myosin light chain (MLC) was determined
after immunoprecipitation and SDS-PAGE protein separation, as
previously reported [15]. In short, after labeling the cells with 50
p.Ci/ml of neutralized, carrier-free sodium [32PJ-orthophosphate,
successive incubations with ST (10 nM, 10 mm) or Ang 11(10 nM),
in the presence or the absence of Z (1 p.M), were performed. Cells
incubated only with buffer, with Z alone or with Z plus Ang II
were used as controls. The reaction was stopped by freezing the
cells in ethanol at —70°C. After solubilizing the proteins, the
supernatants were saved, incubated with human anti-platelet
Fig. 1. Synthesis of cyclic GMP in cultured rat mesangial cells incubated
with somatostatin. Data are the mean SEM of 10 to 15 different
experiments. Abbreviations are: C, cells incubated only with buffer; ST,
cells incubated with 1 M somatostatin; IBMX, cells incubated with 0.5
mM isobutylmethylxanthine; IBMX-ST, cells incubated with 0.5 mM
isobutylmethyixanthine plus 1 jsM somatostatin; Z, cells incubated with 1
sM zaprinast; Z-ST, cells incubated with 1 M zaprinast plus 1 LM
somatostatin. * P < 0.05 vs. C. ** P < 0.05 vs. IBMX or Z.
myosin antibody at 4°C for 90 minutes, and Pansorbin (Calbio-
chem, La Jolla, California, USA) was used to precipitate the
immuno-linked MLC. This fraction was separated by SDS-PAGE,
the gel was frozen and exposed to Kodak XR-5 X-ray films, the
phosphorylated myosin light chain was identified on the autora-
diogram, and its optical density was measured by videodensitom-
etry (Bio-Rad Laboratories, Richmond, California, USA). Results
are expressed in arbitrary density units, corrected for the protein
content.
Statistical methods
Results are expressed as X SEM and the number of experi-
ments are shown in every case. Comparisons were performed by
the paired or unpaired Student's t-test, one-way analysis of
variance, Scheffe's multiple comparison test and Friedman's test
as needed. A P < 0.05 was considered statistically significant.
Results
Figure 1 graphically describes the ability of ST to modify the
synthesis of cGMP in cultured rat mesangial cells under three
experimental conditions: in a basal situation, in the presence of
non-specific phosphodiesterase blockade (IBMX experiments) or
in the presence of a rather specific cGMP phosphodiesterase
blocker (Z experiments). Control cells incubated with IBMX or Z
synthesized a significant higher amount of cGMP than similar
cells without these phosphodiesterase inhibitors, but values were
higher with IBMX. In the three cases, ST significantly increased
cGMP production with respect to the control cells, an effect which
was potentiated by the presence of phosphodiesterase inhibitors.
As shown in Figure 2, which includes experiments performed
without any drug interference, this effect was dose dependent. As
it may be observed, the lowest ST concentration capable of
stimulating cGMP production was 1 n, the maximal effect being
achieved at concentrations between 0.1 and 1 I.LM.
Figure 3 includes data related to the evaluation of the particu-
late guanylate cyclase activity in the presence of ST. The left
pannel shows these data, which are expressed as pmol of cGMP
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synthesized by mg of protein of a particulate cellular fraction
obtained from the cultured cells, when the cellular fraction was
similar in control cells and in cells incubated with ST, as it was
prepared from a pool of different culture flasks (Methods). It can
be observed that ST increased the guanylate cyclase activity by
about four- to fivefold. The right pannel includes similar results,
but in this set of experiments the particulate cellular fraction
obtained from each culture flask was incubated in control condi-
tions and with ST, and this same experimental design was
performed with different flasks. Consequently, the results are
expressed as percent of the control guanylate cyclase activity (1.23
0.35 pmol of cGMP generated/mg protein). In this particular
case, the observed increase in the particulate guanylate cyclase
activity was about threefold.
Figure 4 shows the effect of the specific cGMP-phosphodiester-
ase blockade with zaprinast on the ST-dependent inhibition of the
Ang Il-induced reduction in PCSA of cultured rat mesangial cells.
As shown in the Figure 4 (lower curve), ST alone inhibited the
effect of Ang II in a dose-response manner. This inhibitory effect
was evident at ST concentrations of about 10 nM, and reached a
maximum at 1 !.LM. In contrast, the presence of Z increased the
inhibitory effect of ST (Figure 4, upper curve), as concentrations
as low as 100 M of ST induced a significant blockade of the Ang
Il-dependent reduction in PCSA, with a complete inhibition of
the Mg II effect at 10 flM. In this figure it can be observed that Z
alone, in the absence of ST, did not modify the reduction in PCSA
induced by Ang II.
As changes in PCSA may not reflect true contraction, a similar
analysis to that included in Figure 4 was performed by measuring
myosin light chain phosphoiylation. Results are collected in
Figure 5. Cells incubated with Mg II alone showed a significant
increase in myosin light chain phosphorylation. These effects were
slightly blocked by low ST concentration but not by Z. When cells
were preincubated with zaprinast and then added ST, these same
low ST concentrations decreased myosin light chain phosphory-
lation with respect to control cells. Z alone did not modify myosin
light chain phosphorylation in cultured rat mesangial cells.
Discussion
We have recently demonstrated that ST relaxes cultured rat
mesangial cells [1] by a mechanism independent of the secondary
release of PGE2 or nitric oxide, and also independent of the
intracellular activation of adenylate cyclase or soluble guanylate
cyclase. In the same study it was also demonstrated that ST
inhibited the changes in renal function induced by Mg H, thus
supporting a role for the peptide in the regulation of the
glomerular filtration rate, at least in pathophysiological conditions
[1}. In addition, we have also demonstrated the ability of ST to
inhibit the proliferation of mesangial cells in the presence of fetal
calf serum [2].
The present study points to the possibility that cGMP can be
involved in the genesis of these ST-dependent effects, as the
intracellular levels of this nucleotide increased when cells were
incubated with ST, both in basal conditions and in the presence of
both non-specific or specific phosphodiesterase blockade. In
addition, the dose-response pattern of cGMP synthesis in the
presence of ST paralleled the response obtained when measuring
mesangial cell relaxation [1] or proliferation [2]. However, these
increased levels per se may not constitute an argument supporting
the dependence of the ST effects on cGMP, since it is also
necessary to demonstrate a cause-effect relationship between the
increased cGMP levels and the observed action. For this purpose,
zaprinast, a drug which specifically blocks cGMP phosphodiester-
ase, was selected. It was expected that, if ST relaxes or inhibits the
proliferation of the cells by inducing an increased cellular synthe-
sis of cGMP, zaprinast would potentiate these effects. This was
exactly the result obtained in the present experiments with respect
to relaxation, after following both a morphological and a bio-
chemical experimental approach, thus supporting the importance
of cGMP as a second messenger for the relaxing action of ST.
Moreover, as previously published [2], zaprinast also potentiated
the antiproliferative effect of ST, thus again supporting a role for
cGMP.
From a methodological point of view, some specific comments
with respect to the use of zaprinast must be made. In non-
stimulated cells, the drug induced significantly increased cGMP
synthesis, but the stimulation observed was less impressive than
that obtained with IBMX. Nevertheless, in a situation character-
ized by possibly increased guanylate cyclase activity, as could be
the case in the ST experiments, both zaprinast and IBMX induced
a similar stimulation of cGMP synthesis, thus supporting the
pharmacological role proposed for the drug [16]. This low stimu-
latory effect of zaprinast on cellular cGMP synthesis in basal
conditions may explain the lack of relaxing effect of the drug when
cells were incubated with Mg II. However, by stabilizing the
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Fig. 2. Dose-dependence of cyclic GMP synthesis in cultured rat mesangial
cells incubated with somatostatin. Experiments were performed without
isobutylmethyixanthine or zaprinast. Data are the mean SEM of 5
different experiments. * P < 0.05 vs. C (cells incubated only with buffer).
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Fig. 3. Particulate guanylate cyclase activity and
somatostatin. Results are expressed as the
amount of cyclic GMP generated by a fixed
amount of cultured rat mesangial cell
membrane preparation, and they are the mean
SEM of 8 different experiments. A. Absolute
amount of cOMP generated when cell
membranes were pooled and used together for
the experiments. B. Relative increases of cGMP
when the cell membranes of each particular
culture flask were tested with or without
somatostatin. Abbreviations are: C, membranes
ST incubated only with buffer; ST, membranes
incubated with 1 $LM somatostatin. * P C 0.05
vs. C.
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Fig. 4. Changes of planar cell surface area (PCSA) in cultured rat mesangial
cells in the presence of zaprinast (Z). Cells were incubated with 10 nM
angiotensin II, in the presence of variable concentrations of ST. Experi-
ments were performed with (upper curve) or without (lower curve) Z.
Results are the mean SEM of 4 different experiments. * P C 0.05 vs. 0.
** P C 0.05 vs. without Z.
cUMP generated by ST stimulation, zaprinast clearly potentiated
the relaxation induced by this peptide.
The present results also demonstrate that ST acts by activating
a particulate guanylate cyclase in the mesangial cell membrane.
Different particulate guanylate cyclases have been described, and
it seems that some of them act as receptors for one special kind of
peptides known as natriuretic peptides. Guanylate cyclase A
(GC-A) seems to be the atrial natriuretic peptide (ANP) receptor,
GC-B is the receptor for the C natriuretic peptide and GC-C
responds to different stimuli such as heat-stable enterotoxin
[17—20]. ST shares some properties with some of these substances,
Experimental groups
Fig. 5. Changes in myosin light chain phosphoylation in cultured rat
mesangial cells. Cells were incubated in control conditions (C), with 10 nM
angiotensin II (Ang II), with 10 ni somatostatin plus 10 nM Ang II
(ST-Mg II), with 1 gM zaprinast (Z), with 1 jiM zaprinast plus 10 nM
angiotensin II (Z-Ang II), and with 1 jiM zaprinast plus 10 nM ST plus 10
nM Mg II. Results are the mean SuM of 4 to 7 different experiments. *
C 0.05 vs. C. ** P C 0.05 vs. C and Mg II. P C 0.05 vs. the other
groups.
particularly ANP, as both are able to relax cultured mesangial
cells [8, 21]. We can speculate that by cross reacting with some of
these GC isoforms or even by activating a different, not yet
described GC, ST may modulate the contraction/relaxation of
cultured mesangial cells.
Our results contrast with previous descriptions of second mes-
senger systems for ST [3—7], as they point to the cGMP system as
the mechanism responsible for the relaxation of mesangial cells.
Nevertheless, they do not completely exclude other theoretical
possibilities, such as inhibition of transmembrane calcium fluxes
or increased phosphatase activity in the cells, since these second
messenger systems have been well described for ST [5—7], and
they also might help explain the ST-dependent mesangial cell
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relaxation [6]. Moreover, some relationship may exist between
cGMP, modulation of calcium fluxes and phosphatase activity;
these possible interactions must be explored for ST.
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